Alkem Laboratories Ltd.
NSE: ALKEM · Pharmaceuticals · sector
₹5,030.00NSE close 2026-10-26
Key numbers
Market cap₹60,134 cr
Price₹5,030.00
52w high / low₹5,934 / ₹4,892
P/E27.9xSector median 27.9x
P/B4.3xSector median 2.9x
Book value₹1,156.0
Dividend yield1.02%Sector median 0.48%
ROE16.7%Sector median 11.7%
ROCE19.8%Sector median 12.3%
OPM18.9%Sector median 14.0%
Debt / equity0.12xSector median 0.16x
EV/EBITDA20.8xSector median 18.6x
Interest cover17.2x
Current ratio2.55x
Sales growth 3y+8.2%Sector median +9.6%
Profit growth 3y+32.7%Sector median +13.3%
PEG0.85x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹2,470 cr vs borrowings ₹1,624 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 17.2x in the last 12 months.
- Promoter holding fell by 3.34 percentage points in a year, to 49.70% (2026-06-30).
- Operating cash flow was below net profit in 3 of the last 5 years (FY26, FY25, FY22).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 28% of net profit in the last 12 months.
- Dividend paid in 5 of the last 5 financial years.
- Price ₹5,030.00 on 2026-10-26: -15.2% from the 52-week high, +2.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹6,265.50 · low ₹4,600.35
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| EBITDA | 753 | 759 | 391 | 752 | 921 | 775 | 382 | 766 |
| OPM % | 22.0% | 22.5% | 12.4% | 22.3% | 23.0% | 20.7% | 10.6% | 20.5% |
| Other income | 134 | 93 | 146 | 136 | 104 | 143 | 200 | 153 |
| Net profit | 689 | 626 | 306 | 664 | 765 | 636 | 236 | 520 |
| EPS (₹) | 57.60 | 52.34 | 25.57 | 55.56 | 63.99 | 53.19 | 19.77 | 43.49 |
| Revenue YoY | +17.2% | +10.7% | +14.6% | +10.9% | ||||
| Profit YoY | +11.1% | +1.6% | -22.7% | -21.7% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 10,634 | 11,599 | 12,668 | 12,965 | 14,712 | 15,081 |
| EBITDA | 2,038 | 1,506 | 2,124 | 2,512 | 2,830 | 2,844 |
| Net profit | 1,646 | 984 | 1,796 | 2,165 | 2,302 | 2,158 |
| EPS (₹) | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 | 180.44 |
| Revenue growth | +9.1% | +9.2% | +2.3% | +13.5% | +13.4% | |
| Profit growth | -40.2% | +82.5% | +20.6% | +6.3% | -5.6% | |
| Dividend / share (₹) | 35.00 | 19.00 | 45.00 | 42.00 | 51.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +8.2% | +15.3% | +13.4% |
| Net profit | +32.7% | +6.4% | -5.6% |
| EPS | +32.7% | +6.4% | – |
| Share price | – | -9.8% (2y) | -9.6% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 9,045 | 10,312 | 11,985 | 13,820 |
| Borrowings | – | 1,397 | 1,214 | 1,063 | 1,624 |
| Cash & equivalents | – | 2,934 | 1,728 | 2,465 | 2,470 |
| Total assets | – | 13,757 | 15,575 | 17,691 | 20,873 |
| Fixed assets | – | 2,065 | 2,161 | 2,064 | 2,695 |
| Capital work in progress | – | 310 | 148 | 477 | 138 |
| Investments | – | 305 | 335 | 943 | 1,132 |
| Receivables | – | 2,132 | 2,253 | 2,466 | 2,979 |
| Inventory | – | 2,608 | 2,661 | 2,922 | 3,333 |
| Payables | – | 1,165 | 1,748 | 1,839 | 2,244 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 1,111 | 1,682 | 1,948 | 1,913 | 1,963 |
| Cash from investing | -1,435 | 113 | -1,009 | -1,299 | -1,667 |
| Cash from financing | 380 | -1,761 | -1,145 | -811 | -503 |
| Capex | 339 | 233 | 259 | 676 | 617 |
| Free cash flow | 772 | 1,450 | 1,689 | 1,237 | 1,346 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 10.9% | 17.4% | 18.1% | 16.7% |
| ROCE % | – | 13.5% | 18.5% | 20.3% | 19.6% |
| Debtor days | – | 67 | 65 | 69 | 74 |
| Inventory days | – | 194 | 197 | 224 | 239 |
| Payable days | – | 87 | 129 | 141 | 161 |
| Cash conversion cycle (days) | – | 174 | 133 | 152 | 152 |
| Working capital days | – | 154 | 185 | 193 | 184 |
Shareholding
| Holder | % (2026-06-30) |
|---|---|
| Promoters | 49.70% |
| FIIs | 10.42% |
| DIIs | 22.63% |
| of which Mutual funds | 16.71% |
| of which Insurance | 4.13% |
| Public (non-institutions) | 17.25% |
| Quarter | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 55.66% | 55.66% | 55.13% | 53.04% | 51.20% | 51.20% | 51.20% | 49.70% |
| Promoter group | % |
|---|---|
| Sarandhar Singh * (please refer notes) | 18.29% |
| Basudeo Narain Singh | 7.27% |
| Mritunjay Kumar Singh | 6.42% |
| Madhurima Singh& (please refer notes) | 6.18% |
| Madhurima Singh@ (please refer notes) | 2.59% |
| Seema Singh | 2.16% |
| Archana Singh | 2.00% |
| Aniruddha Singh& (please refer notes) | 1.01% |
| Divya Singh& (please refer notes) | 1.01% |
| Meghna Singh | 1.01% |
| Shrey Shree Anant Singh | 1.00% |
| Raj Kumar Singh | 0.45% |
| Srinivas Singh # (please refer notes) | 0.09% |
| Manju Singh # (please refer notes) | 0.08% |
| Sarandhar Singh # (please refer notes) | 0.07% |
| Public holders above 1% | % |
|---|---|
| Hdfc Mutual Fund - Hdfc Mid-Cap Fund | 4.77% |
| Icici Prudential Multi-Asset Fund | 3.57% |
| Kishor Kumar Singh | 2.49% |
| Alok Kumar | 2.31% |
| Ashok Kumar | 2.25% |
| Deepak Kumar Singh | 2.01% |
| Sbi Large & Midcap Fund | 1.99% |
| Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund | 1.87% |
| Dsp Midcap Fund | 1.78% |
| Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I | 1.46% |
| Life Insurance Corporation Of India - P & Gs Fund | 1.43% |
| Rajesh Kumar | 1.41% |
| Hdfc Life Insurance Company Limited | 1.31% |
| Rajeev Ranjan | 1.24% |
62,822 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ALKEM | ₹60,134 cr | 27.9x | 4.3x | 16.7% | 19.8% | 18.9% | +8.2% | 1.02% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-08-07 | Dividend | Dividend - Rs 10 Per Share |
| 2026-02-20 | Dividend | Interim Dividend - Rs 43 Per Share |
| 2025-08-08 | Dividend | Dividend - Rs 8 Per Share |
| 2025-02-14 | Dividend | Interim Dividend - Rs 37 Per Share |
| 2024-08-09 | Dividend | Dividend - Rs 5 Per Share |
| 2024-02-16 | Dividend | Interim Dividend - Rs 35 Per Share |
| 2023-08-10 | Dividend | Dividend - Rs 10 Per Share |
| 2023-02-17 | Dividend | Interim Dividend - Rs 15 Per Share & Special Dividend Rs 25 Per Share |
| 2022-08-08 | Dividend | Dividend - Rs 4 Per Share |
| 2022-02-10 | Dividend | Interim Dividend - Rs 30 Per Sh |
| 2021-08-09 | Dividend | Dividend - Rs 5 Per Share |
| 2021-02-11 | Dividend | Interim Dividend - Rs 25 Per Share |
| 2020-08-10 | Dividend | Annual General Meeting/Dividend - Rs 3 Per Share |
| 2020-02-13 | Dividend | Interim Dividend - Rs 22 Per Share |
| 2019-08-19 | Dividend | Annual General Meeting/Dividend - Rs 8 Per Share |
| 2019-02-15 | Dividend | Interim Dividend - Rs 8 Per Share |
| 2018-08-23 | Dividend | Annual General Meeting/Dividend- Rs 7 Per Share |
| 2018-02-16 | Dividend | Interim Dividend - Rs 6 Per Share (Purpose Revised) |
| 2017-08-31 | Dividend | Annual General Meeting/ Dividend -Rs 9/- Per Share |
| 2016-11-23 | Dividend | Interim Dividend Rs 6/- Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing of pharmaceutical products: The Company is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical products.
- Trade: Wholesale Trading
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ALKEM |
| BSE code | 539523 |
| ISIN | INE540L01014 |
| Face value | ₹2.0 |
| Incorporated | 1973-08-08 |
| Website | www.alkemlabs.com |
| Plants (India / abroad) | 12 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.